MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

170.7B

Vuru Grade

47.84/100

Current Price

$59.19
-0.295 (-0.50%)

Growth Price

$46.98
Overvalued by 20.63%

Stability Price

$23.38
Overvalued by 60.50%

Company Metrics

  • 31.34 P/E
  • 3.94 P/S
  • 3.57 P/B
  • 1.898 EPS
  • 10.80% Cash ROIC
  • 0.98 Cash Ratio
  • 1.75 / 2.94% Dividend
  • 8.22M Avg. Vol.
  • 2.88B Shares
  • 170.7B Market Cap.

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Why Wall Street Is Not Bearish On Merck
Bidness Etc - 5 hours ago
None of the analysts covering Merck & Co., Inc. (MRK) are bearish due to the company's strong drug pipeline. However, many are not completely sure of Merck's future and have a neutral stance on the pharmaceutical.
3 Reasons Merck & Co., Inc.'s Stock Could Rise
Motley Fool - Aug 19, 2014
For investors lucky enough to have jumped into Merck (NYSE: MRK ) in 2009 at the tail end of the Great Recession you've seen an appreciation in your shares of near 100%.
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on August 18
Equities.com - Aug 18, 2014
Shares of Merck & Co. Inc. led all laggers on the Dow Monday with a decline of 0.32%. The DJIA closed at 16,838.70, which is a 1.06% change from the previous day's close.
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on August 21
Equities.com - 1 hour ago
Shares of Merck & Co. Inc. led all laggers on the Dow Thursday with a decline of 1.06%. The DJIA closed at 17,039.60, which is a 0.36% change from the previous day's close.
Merck & Co., Inc. (MRK): The Grand Daddy of Pharma
ETF Daily News - 6 hours ago
Right now, Merck & Co., Inc.(NYSE:MRK), this nation's second biggest pharmaceutical maker, is a curious animal: a value stock that's priced like a growth stock.
Merck's Sleeping Pill-Belsomra: Approved
Bidness Etc - Aug 14, 2014
Merck & Co., Inc. (MRK), the second-largest US pharmaceutical company, stock closed 1.44% higher yesterday, and continued to gain during extended trading, after the Food and Drug Administration (FDA) approved the company's experimental drug, ...
Merck & Co. Inc (NYSE:MRK) The Insomniac's Wish, Perrigo Company PLC ... - SmallCap Network
FDA Approves New Sleeping Drug From Merck - ABC News
5 Things Merck & Co., Inc.'s Management Wants You to Know
NASDAQ - Aug 11, 2014
In its second-quarter earnings results, released just two weeks ago, Merck reported a 1% decline in worldwide sales to $10.9 billion from the year-ago period, weighed-down by patent expirations and increasing competition, as its adjusted earnings per ...
One Put, One Call Option To Know About for Merck & Co.
Forbes - Aug 11, 2014
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co Merck & Co., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract ...
Merck & Co. Inc.: I'm Long, But It Screams Overvalued Today (MRK)
Seeking Alpha - Jul 24, 2014
... I wrote that article at the beginning of 2014 I felt KO was undervalued, purchased it and am now sitting on a nice 8.2% return, excluding dividends, in just over half a year.
Merck & Co., Inc. (MRK) Tops Q2 EPS by 5c
StreetInsider.com (subscription) - Jul 29, 2014
Merck & Co., Inc. (NYSE: MRK) reported Q2 EPS of $0.85, $0.05 better than the analyst estimate of $0.80. Revenue for the quarter came in at $10.93 billion versus the consensus estimate of $10.6 billion.
Merck & Co., Inc. (MRK) Releases FY14 Earnings Guidance - WKRB News
Merck & Co., Inc. Posts Higher Q2 Profits; Revenue Declines; Beats Estimates ... - Dividend.com